Skip to main content
Log in

Survival from breast cancer in patients with CHEK2 mutations

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript


The purpose of this study is to estimate 10-year survival rates for patients with early onset breast cancer, with and without a CHEK2 mutation and to identify prognostic factors among CHEK2-positive breast cancer patients. 3,592 women with stage I to stage III breast cancer, diagnosed at or below age 50, were tested for four founder mutations in the CHEK2 gene. Information on tumor characteristics and on treatments received was retrieved from medical records. Dates of death were obtained from the Poland Vital Statistics Registry. Survival curves were generated for the mutation-positive and -negative sub-cohorts. Predictors of survival were determined among CHEK2 carriers using the Cox proportional hazards model. 3,592 patients were eligible for the study, of whom 140 (3.9 %) carried a CHEK2-truncating mutation and 347 (9.7 %) carried a missense mutation. The mean follow-up was 8.9 years. The 10-year survival for all CHEK2 mutation carriers was 78.8 % (95 % CI 74.6–83.2 %) and for non-carriers was 80.1 % (95 % CI 78.5–81.8 %). Among women with a CHEK2-positive breast cancer, the adjusted hazard ratio associated with ER-positive status was 0.88 (95 % CI 0.48–1.62). Among women with an ER-positive breast cancer, the adjusted hazard ratio associated with a CHEK2 mutation was 1.31 (95 % CI 0.97–1.77). The survival of women with breast cancer and a CHEK2 mutation is similar to that of patients without a CHEK2 mutation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others


  1. Cybulski C, Górski B, Huzarski T, Byrski T, Gronwald J, Debniak T, Wokolorczyk D, Jakubowska A, Kowalska E, Oszurek O, Narod SA, Lubinski J (2006) CHEK2-positive breast cancers in young Polish women. Clin Cancer Res 12:4832–4835

    Article  CAS  PubMed  Google Scholar 

  2. Cybulski C, Wokołorczyk D, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Masojć B, Deebniak T, Górski B, Blecharz P, Narod SA, Lubiński J (2011) Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 29:3747–3752

    Article  CAS  PubMed  Google Scholar 

  3. Cybulski C, Huzarski T, Byrski T, Gronwald J, Debniak T, Jakubowska A, Gorski B, Wokolorczyk D, Masojc B, Narod SA, Lubinski J (2009) Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention. Clin Genet 75:72–78

    Article  CAS  PubMed  Google Scholar 

  4. Weischer M, Nordestgaard BG, Pharoah P et al (2012) CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol 30:4308–4316

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Tryggvadottir L, Olafsdottir EJ, Olafsdottir GH, Sigurdsson H, Johannsson OT, Bjorgvinsson E, Alexiusdottir K, Stefansson OA, Agnarsson BA, Narod SA, Eyfjord JE, Jonasson JG (2013) Tumour diploidy and survival in breast cancer patients with BRCA2 mutations. Breast Cancer Res Treat 140:375–384

    Article  CAS  PubMed  Google Scholar 

  6. Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, Van’t Veer LJ (2007) Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol 25:64–69

    Article  CAS  PubMed  Google Scholar 

  7. De Bock GH, Schutte M, Krol-Warmerdam EM, Seynaeve C, Blom J, Brekelmans CT, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, Devilee P, Tollenaar RA, Klijn JG (2004) Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet 41:731–735

    Article  PubMed Central  PubMed  Google Scholar 

  8. Meyer A, Dörk T, Sohn C, Karstens JH, Bremer M (2007) Breast cancer in patients carrying a germ-line CHEK2 mutation: outcome after breast conserving surgery and adjuvant radiotherapy. Radiother Oncol 82:349–353

    Article  CAS  PubMed  Google Scholar 

Download references


The work described in this article was funded by the Polish Ministry of Health.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations


Corresponding author

Correspondence to S. A. Narod.

Additional information

Other members of the Polish Hereditary Breast Cancer Consortium are listed in "Appendix".



Błasińska-Morawiec M, Chosia M, Drosik K, Gozdecka-Grodecka S, Goźdź S, Grzybowska E, Haus O, Jeziorski A, Karczewska A, Kordek R, Kozak A, Kozak-Klonowska B, Lamperska K, Lange D, Mackiewicz A, Mituś J, Niepsuj S, Oszurek O, Gugala K, Morawiec Z, Mierzwa T, Posmyk M, Rozmiarek A, Ryś J, Szczylik C, Uciński M, Urbański K, Waśko B, Wandzel P and the Polish Breast Cancer Consortium.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huzarski, T., Cybulski, C., Wokolorczyk, D. et al. Survival from breast cancer in patients with CHEK2 mutations. Breast Cancer Res Treat 144, 397–403 (2014).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: